| Title |
Omega-3 polyunsaturated fatty acids as adjuvant therapy of colorectal cancer
|
|---|---|
| Published in |
Cancer and Metastasis Reviews, July 2018
|
| DOI | 10.1007/s10555-018-9744-y |
| Pubmed ID | |
| Authors |
Milene Volpato, Mark A. Hull |
| Abstract |
The majority of evidence linking anti-colorectal cancer (CRC) activity with omega-3 polyunsaturated fatty acids (O3FAs) has focussed on decreased CRC risk (prevention). More recently, preclinical data and human observational studies have begun to make the case for adjuvant treatment of advanced CRC. Herein, we review latest data regarding the effect of O3FAs on post-diagnosis CRC outcomes, including mechanistic preclinical data, evidence that O3FAs have beneficial effects on efficacy and tolerability of CRC chemotherapy, and human epidemiological data linking dietary O3FA intake with CRC outcomes. We also highlight ongoing randomised controlled trials of O3FAs with CRC endpoints and discuss critical gaps in the evidence base, which include limited understanding of the effects of O3FAs on the tumour microenvironment, the host immune response to CRC, and the intestinal microbiome. |
X Demographics
The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 4 | 31% |
| Spain | 1 | 8% |
| Austria | 1 | 8% |
| United States | 1 | 8% |
| Unknown | 6 | 46% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 11 | 85% |
| Scientists | 2 | 15% |
Mendeley readers
The data shown below were compiled from readership statistics for 133 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 133 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 19 | 14% |
| Student > Bachelor | 19 | 14% |
| Student > Master | 13 | 10% |
| Student > Ph. D. Student | 9 | 7% |
| Professor | 7 | 5% |
| Other | 27 | 20% |
| Unknown | 39 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 18% |
| Biochemistry, Genetics and Molecular Biology | 20 | 15% |
| Nursing and Health Professions | 9 | 7% |
| Agricultural and Biological Sciences | 7 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 3% |
| Other | 16 | 12% |
| Unknown | 53 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 December 2018.
All research outputs
#4,648,901
of 25,701,027 outputs
Outputs from Cancer and Metastasis Reviews
#137
of 880 outputs
Outputs of similar age
#81,442
of 342,287 outputs
Outputs of similar age from Cancer and Metastasis Reviews
#3
of 16 outputs
Altmetric has tracked 25,701,027 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 880 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,287 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.